Company news

Lexicon Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 5, 2025

Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

July 30, 2025

Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

July 22, 2025

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

July 17, 2025

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

June 22, 2025

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

June 17, 2025

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 28, 2025

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

May 19, 2025

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

May 12, 2025

Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

May 5, 2025

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

May 5, 2025

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

April 1, 2025

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

March 27, 2025

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

March 6, 2025

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

March 5, 2025

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

March 3, 2025

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

March 3, 2025

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

March 1, 2025

Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

February 17, 2025

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

January 20, 2025

Lexicon Appoints Scott Coiante as Chief Financial Officer

January 1, 2025

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

December 19, 2024

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

November 25, 2024

Lexicon Pharmaceuticals to Participate in December Investor Conferences

November 24, 2024

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

November 21, 2024

Lexicon Appoints Ivan H. Cheung to Board of Directors

November 19, 2024

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago

November 13, 2024

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

November 11, 2024

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference

November 5, 2024

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

November 4, 2024

Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024

November 4, 2024

Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss

November 3, 2024

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

October 30, 2024

New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024

October 22, 2024

Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

October 21, 2024

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

October 15, 2024

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

September 26, 2024

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

September 15, 2024

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes

September 9, 2024

New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration

September 2, 2024

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

September 2, 2024

Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista

August 20, 2024

Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio

August 12, 2024

Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists

August 6, 2024

Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

July 31, 2024

Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024

July 24, 2024

Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

July 15, 2024

New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure

July 14, 2024

Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

July 7, 2024

Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes

June 20, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 21 decks. Every deck is listed under its year.